Obstructive Sleep Apnea: Implications for Cardiac and Vascular Disease

Abu S M Shamsuzzaman, Bernard J. Gersh, Virend Somers

Research output: Contribution to journalArticle

884 Citations (Scopus)

Abstract

Context: Obstructive sleep apnea (OSA) has been increasingly implicated in the initiation and progression of cardiovascular diseases. Objective: To systematically review the interactions of OSA with cardiovascular pathophysiology and diseases. Data Sources and Study Selection: The MEDLINE database from January 1966 to March 2003 was searched using the Medical Subject Headings sleep, sleep apnea, obesity, hypertension, heart failure, cardiac arrhythmia, coronary artery disease, stroke, sympathetic activity, endothelium, inflammation, and continuous positive airway pressure (CPAP) to identify peer-reviewed studies of OSA. Priority was given to large prospective cohort studies and to randomized controlled trials. Data Extraction: We identified 154 original investigations and reviews of sleep-related breathing disorders. Data from these studies were examined for relevance and extracted by one of the authors. Data Synthesis: Approximately 1 in 5 adults has at least mild OSA (apnea-hypopnea index [ie, the number of apneic and hypopneic events per hour], 5-15), and 1 in 15 adults has at least moderate OSA (apnea-hypopnea index, 15-30). Repetitive apneic events disrupt the normal physiologic interactions between sleep and the cardiovascular system. Such sleep fragmentation, as well as abnormalities evident in patients with OSA (eg, increased sympathetic activation, vascular endothelial dysfunction, increased oxidative stress, inflammation, increased platelet aggregability, metabolic dysregulation), may be implicated in the initiation and progression of cardiac and vascular disease. Persuasive data implicate OSA in the development of hypertension, and OSA also may contribute to cardiac ischemia, congestive heart failure, cardiac arrhythmias, and perhaps also to cerebrovascular disease and stroke. Conclusions: Obstructive sleep apnea is common, readily diagnosed, and usually treatable. It frequently coexists undiagnosed in patients with cardiovascular disease, activates disease mechanisms known to elicit cardiac and vascular damage, and may be implicated in progression of cardiovascular disease and resistance to conventional therapeutic strategies. In the absence of definitive evidence from large-scale trials and a better understanding of potential cost-effectiveness, the likely benefits of diagnosis and treatment of OSA are presently best appraised on an individualized patient basis.

Original languageEnglish (US)
Pages (from-to)1906-1914
Number of pages9
JournalJournal of the American Medical Association
Volume290
Issue number14
DOIs
StatePublished - Oct 8 2003

Fingerprint

Obstructive Sleep Apnea
Vascular Diseases
Heart Diseases
Cardiovascular Diseases
Sleep
Apnea
Blood Vessels
Cardiac Arrhythmias
Heart Failure
Stroke
Medical Subject Headings
Hypertension
Inflammation
Cerebrovascular Disorders
Disease Resistance
Continuous Positive Airway Pressure
Sleep Deprivation
Information Storage and Retrieval
Sleep Apnea Syndromes
Cardiovascular System

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Obstructive Sleep Apnea : Implications for Cardiac and Vascular Disease. / Shamsuzzaman, Abu S M; Gersh, Bernard J.; Somers, Virend.

In: Journal of the American Medical Association, Vol. 290, No. 14, 08.10.2003, p. 1906-1914.

Research output: Contribution to journalArticle

Shamsuzzaman, Abu S M ; Gersh, Bernard J. ; Somers, Virend. / Obstructive Sleep Apnea : Implications for Cardiac and Vascular Disease. In: Journal of the American Medical Association. 2003 ; Vol. 290, No. 14. pp. 1906-1914.
@article{6edaf74e4f9649f4a99a5cac907bc4a9,
title = "Obstructive Sleep Apnea: Implications for Cardiac and Vascular Disease",
abstract = "Context: Obstructive sleep apnea (OSA) has been increasingly implicated in the initiation and progression of cardiovascular diseases. Objective: To systematically review the interactions of OSA with cardiovascular pathophysiology and diseases. Data Sources and Study Selection: The MEDLINE database from January 1966 to March 2003 was searched using the Medical Subject Headings sleep, sleep apnea, obesity, hypertension, heart failure, cardiac arrhythmia, coronary artery disease, stroke, sympathetic activity, endothelium, inflammation, and continuous positive airway pressure (CPAP) to identify peer-reviewed studies of OSA. Priority was given to large prospective cohort studies and to randomized controlled trials. Data Extraction: We identified 154 original investigations and reviews of sleep-related breathing disorders. Data from these studies were examined for relevance and extracted by one of the authors. Data Synthesis: Approximately 1 in 5 adults has at least mild OSA (apnea-hypopnea index [ie, the number of apneic and hypopneic events per hour], 5-15), and 1 in 15 adults has at least moderate OSA (apnea-hypopnea index, 15-30). Repetitive apneic events disrupt the normal physiologic interactions between sleep and the cardiovascular system. Such sleep fragmentation, as well as abnormalities evident in patients with OSA (eg, increased sympathetic activation, vascular endothelial dysfunction, increased oxidative stress, inflammation, increased platelet aggregability, metabolic dysregulation), may be implicated in the initiation and progression of cardiac and vascular disease. Persuasive data implicate OSA in the development of hypertension, and OSA also may contribute to cardiac ischemia, congestive heart failure, cardiac arrhythmias, and perhaps also to cerebrovascular disease and stroke. Conclusions: Obstructive sleep apnea is common, readily diagnosed, and usually treatable. It frequently coexists undiagnosed in patients with cardiovascular disease, activates disease mechanisms known to elicit cardiac and vascular damage, and may be implicated in progression of cardiovascular disease and resistance to conventional therapeutic strategies. In the absence of definitive evidence from large-scale trials and a better understanding of potential cost-effectiveness, the likely benefits of diagnosis and treatment of OSA are presently best appraised on an individualized patient basis.",
author = "Shamsuzzaman, {Abu S M} and Gersh, {Bernard J.} and Virend Somers",
year = "2003",
month = "10",
day = "8",
doi = "10.1001/jama.290.14.1906",
language = "English (US)",
volume = "290",
pages = "1906--1914",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "14",

}

TY - JOUR

T1 - Obstructive Sleep Apnea

T2 - Implications for Cardiac and Vascular Disease

AU - Shamsuzzaman, Abu S M

AU - Gersh, Bernard J.

AU - Somers, Virend

PY - 2003/10/8

Y1 - 2003/10/8

N2 - Context: Obstructive sleep apnea (OSA) has been increasingly implicated in the initiation and progression of cardiovascular diseases. Objective: To systematically review the interactions of OSA with cardiovascular pathophysiology and diseases. Data Sources and Study Selection: The MEDLINE database from January 1966 to March 2003 was searched using the Medical Subject Headings sleep, sleep apnea, obesity, hypertension, heart failure, cardiac arrhythmia, coronary artery disease, stroke, sympathetic activity, endothelium, inflammation, and continuous positive airway pressure (CPAP) to identify peer-reviewed studies of OSA. Priority was given to large prospective cohort studies and to randomized controlled trials. Data Extraction: We identified 154 original investigations and reviews of sleep-related breathing disorders. Data from these studies were examined for relevance and extracted by one of the authors. Data Synthesis: Approximately 1 in 5 adults has at least mild OSA (apnea-hypopnea index [ie, the number of apneic and hypopneic events per hour], 5-15), and 1 in 15 adults has at least moderate OSA (apnea-hypopnea index, 15-30). Repetitive apneic events disrupt the normal physiologic interactions between sleep and the cardiovascular system. Such sleep fragmentation, as well as abnormalities evident in patients with OSA (eg, increased sympathetic activation, vascular endothelial dysfunction, increased oxidative stress, inflammation, increased platelet aggregability, metabolic dysregulation), may be implicated in the initiation and progression of cardiac and vascular disease. Persuasive data implicate OSA in the development of hypertension, and OSA also may contribute to cardiac ischemia, congestive heart failure, cardiac arrhythmias, and perhaps also to cerebrovascular disease and stroke. Conclusions: Obstructive sleep apnea is common, readily diagnosed, and usually treatable. It frequently coexists undiagnosed in patients with cardiovascular disease, activates disease mechanisms known to elicit cardiac and vascular damage, and may be implicated in progression of cardiovascular disease and resistance to conventional therapeutic strategies. In the absence of definitive evidence from large-scale trials and a better understanding of potential cost-effectiveness, the likely benefits of diagnosis and treatment of OSA are presently best appraised on an individualized patient basis.

AB - Context: Obstructive sleep apnea (OSA) has been increasingly implicated in the initiation and progression of cardiovascular diseases. Objective: To systematically review the interactions of OSA with cardiovascular pathophysiology and diseases. Data Sources and Study Selection: The MEDLINE database from January 1966 to March 2003 was searched using the Medical Subject Headings sleep, sleep apnea, obesity, hypertension, heart failure, cardiac arrhythmia, coronary artery disease, stroke, sympathetic activity, endothelium, inflammation, and continuous positive airway pressure (CPAP) to identify peer-reviewed studies of OSA. Priority was given to large prospective cohort studies and to randomized controlled trials. Data Extraction: We identified 154 original investigations and reviews of sleep-related breathing disorders. Data from these studies were examined for relevance and extracted by one of the authors. Data Synthesis: Approximately 1 in 5 adults has at least mild OSA (apnea-hypopnea index [ie, the number of apneic and hypopneic events per hour], 5-15), and 1 in 15 adults has at least moderate OSA (apnea-hypopnea index, 15-30). Repetitive apneic events disrupt the normal physiologic interactions between sleep and the cardiovascular system. Such sleep fragmentation, as well as abnormalities evident in patients with OSA (eg, increased sympathetic activation, vascular endothelial dysfunction, increased oxidative stress, inflammation, increased platelet aggregability, metabolic dysregulation), may be implicated in the initiation and progression of cardiac and vascular disease. Persuasive data implicate OSA in the development of hypertension, and OSA also may contribute to cardiac ischemia, congestive heart failure, cardiac arrhythmias, and perhaps also to cerebrovascular disease and stroke. Conclusions: Obstructive sleep apnea is common, readily diagnosed, and usually treatable. It frequently coexists undiagnosed in patients with cardiovascular disease, activates disease mechanisms known to elicit cardiac and vascular damage, and may be implicated in progression of cardiovascular disease and resistance to conventional therapeutic strategies. In the absence of definitive evidence from large-scale trials and a better understanding of potential cost-effectiveness, the likely benefits of diagnosis and treatment of OSA are presently best appraised on an individualized patient basis.

UR - http://www.scopus.com/inward/record.url?scp=0141922797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141922797&partnerID=8YFLogxK

U2 - 10.1001/jama.290.14.1906

DO - 10.1001/jama.290.14.1906

M3 - Article

C2 - 14532320

AN - SCOPUS:0141922797

VL - 290

SP - 1906

EP - 1914

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 14

ER -